Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia

Michael Andreeff, MD PhD, Jianfang Zeng, MD, Alice Soragni, PhD, Vivian Ruvolo, Bing Z Carter, PhD, Jo Ishizawa, MD PhD, Jared K. Burks, PhD, David Eisenberg, PhD

Blood (2019) 134 (Supplement_1): 3786.

https://doi.org/10.1182/blood-2019-130900

Published: 2019

Journal Articles

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Feng Wang, PhD, Koichi Takahashi, MD, Po Yee Mak, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1251.

https://doi.org/10.1182/blood-2019-127182

Published: 2019

Journal Articles

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Rafael Heinz Montoya, Naval G. Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2556.

https://doi.org/10.1182/blood-2019-126950

Published: 2019

Journal Articles

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Ran Zhao, BS, Sarah Zarabi, MD, Takenobu Nii, PhD, Ondrej Halgas, PhD, Yulia Jitkova, PhD, Vivian Ruvolo, Lauren Heese, Yuki Nishida, MD PhD, Gautam M. Borthakur, MD, Kensuke Kojima, MD PhD, Martin Stogniew, Wolfgang Oster, MD, Emil Pai, PhD, Eric Davis, MD, Hagop M. Kantarjian, MD, Aaron D Schimmer, MD PhD, Michael Andreeff, MD PhD, Jo Ishizawa, MD PhD

Blood (2019) 134 (Supplement_1): 2562.

https://doi.org/10.1182/blood-2019-127101

Published: 2019

Journal Articles

TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2629.

https://doi.org/10.1182/blood-2018-99-113900

Published: 2018

Journal Articles

Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells

Jo Ishizawa, MD PhD, Ran Zhao, Lauren Heese, Alex Jaeger, PhD, Yuki Nishida, Rodrigo Jacamo, PhD, Kensuke Kojima, MD PhD, Man Chun John MA, PhD, Vivian Ruvolo, PhD, Dhruv Chachad, R. Eric Davis, MD, William Devine, PhD, John A Porco, Jr., PhD, Luke Whitesell, MD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2637.

https://doi.org/10.1182/blood.V130.Suppl_1.2637.2637

Published: 2017

Journal Articles

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Vivian Ruvolo, PhD, Neel Madhukar, Ran Zhao, Hong Mu, MD PhD, Lauren Heese, Kensuke Kojima, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Neil Charter, Sean Deacon, Olivier Elemento, PhD, Joshua E. Allen, PhD, Wolfgang Oster, MD, Martin Stogniew, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2616.

https://doi.org/10.1182/blood.V130.Suppl_1.2616.2616

Published: 2017

Journal Articles

The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism

Dhruv Chachad, Jo Ishizawa, MD PhD, Wayne R Danter, MD, Gordon Mills, MD PhD, Michael Andreeff, MD PhD, Kensuke Kojima, MD, PhD

Blood (2016) 128 (22): 2757.

https://doi.org/10.1182/blood.V128.22.2757.2757

Published: 2016

Journal Articles

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Gautam Borthakur, MD, Jo Ishizawa, MD PhD, Courtney D DiNardo, MD, Tapan M. Kadia, MD, Katherine Weise, Joshua E Allen, PhD, Wolfgang Oster, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 3997.

https://doi.org/10.1182/blood.V128.22.3997.3997

Published: 2016

Journal Articles

Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b

Jo Ishizawa, MD PhD, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, MD PhD, Dhruv Chachad, Courtney D DiNardo, MD, Sherry Pierce, BSN, BA, Keyur P. Patel, MD PhD, Archie Tse, R Eric Davis, MD, Arvind Rao, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 2893.

https://doi.org/10.1182/blood.V128.22.2893.2893

Published: 2016

Journal Articles

ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Ran Zhao, Jianfang Zeng, MD PhD, Dhruv Chachad, Kensuke Kojima, MD PhD, Marina Konopleva, MD PhD, Richard Eric Davis, MD, Joshua E Allen, PhD, Martin Stogniew, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 4059.

https://doi.org/10.1182/blood.V128.22.4059.4059

Published: 2016

Journal Articles

Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach

Jo Ishizawa, MD PhD, Rodrigo Omar Jacamo, PhD, Kensuke Kojima, MD PhD, Dhruv Chachad, MS, Vivian Ruvolo, MS, Peter Ruvolo, PhD, Weiguo Zang, PhD, Yoko Tabe, MD PhD, Marina Konopleva, MD PhD, William Devine, PhD, Susan Lindquist, PhD, John A Porco, Jr., Luke Whitesell, MD PhD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 2548.

https://doi.org/10.1182/blood.V126.23.2548.2548

Published: 2015

Journal Articles

Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3 -Mutated Acute Myeloid Leukemias

Weiguo Zhang, MD, PhD, Jo Ishizawa, MD PhD, Hong Mu, MD PhD, Naval Daver, MD, Vivian Ruvolo, MS, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 1266.

https://doi.org/10.1182/blood.V126.23.1266.1266

Published: 2015

Journal Articles

ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response

Blood (2015) 126 (23): 2051.

https://doi.org/10.1182/blood.V126.23.2051.2051

Published: 2015

Journal Articles

ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies

Joshua E. Allen, PhD, Jo Ishizawa, MD PhD, Wafik S. El-Deiry, MD PhD F.A.C.P, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 4812.

https://doi.org/10.1182/blood.V124.21.4812.4812

Published: 2014

Journal Articles

ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition

Jo Ishizawa, MD PhD, Kensuke Kojima, MD PhD, Dhruv Chachad, MS, Peter P. Ruvolo, PhD, Vivian R Ruvolo, MA, Rodrigo Jacamo, PhD, Archana Dilip, MS, Hong Mu, MD PhD, Zhihong Zeng, MD, Polina Matre, PhD, Joshua E. Allen, PhD, Sattva S Neelapu, MD, Timothy J. McDonnell, MD PhD, Roberto N. Miranda, MD, Larry W. Kwak, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, R Eric Davis, MD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 3122.

https://doi.org/10.1182/blood.V124.21.3122.3122

Published: 2014

Journal Articles

ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples

Varun Vijay Prabhu, Jo Ishizawa, MD PhD, Dan Zhao, MD PhD, Joshua E. Allen, PhD, Tracy T. Batchelor, MD, Andrew S. Chi, MD PhD, Michael Andreeff, MD PhD, Wafik S. El-Deiry, MD PhD F.A.C.P

Blood (2014) 124 (21): 5219.

https://doi.org/10.1182/blood.V124.21.5219.5219

Published: 2014

Journal Articles

Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia

Yuki Nishida, MD, Kensuke Kojima, MD PhD, Aya Maeda, Dhruv Chachad, MS, Hiroaki Kitamura, MD, Jo Ishizawa, MD PhD, Michael Andreef, MD PhD, Steven M. Kornblau, MD, Shinya Kimura, MD

Blood (2014) 124 (21): 3617.

https://doi.org/10.1182/blood.V124.21.3617.3617

Published: 2014

Journal Articles

ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas

Jo Ishizawa, MD, PhD, Kensuke Kojima, MD, PhD, Archana Dilip, MS, Vivian R Ruvolo, MA, Bing Z Carter, PhD, Joshua E Allen, PhD, Sattva S. Neelapu, MD, Timothy J. McDonnell, MD, PhD, Mala Kiran Talekar, MD, Wafik S. El-Deiry, MD, Larry W. Kwak, MD, PhD, Michael Andreeff, MD, PhD

Blood (2013) 122 (21): 3822.

https://doi.org/10.1182/blood.V122.21.3822.3822

Published: 2013

NARROW

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors

Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b

ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies

Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach

Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3 -Mutated Acute Myeloid Leukemias

ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response

ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies

ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition

ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples

Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia

ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only